Abstract
Leukemia is a severe cancer of the blood and the most common treatment for acute myeloid leukemia (AML), a severe and aggressive type of leukemia, is intensive chemotherapy. The latter involves exposure of the patient to cytotoxic drugs which interact with highly proliferative cells. More specifically, only cells that are in specific phases of the cell cycle will be eliminated. Since healthy cells also proliferate in order to renew the cellular material. Therefore, “closing the loop” from in vivo to in vitro and in silico is a first step towards optimization and personalization of chemotherapy treatment. Clinical treatment protocols ignore the mechanisms behind drug action on the normal and abnormal populations. The main models are pharmacokinetics (PK), which describes the elimination of the drug by the organs, and pharmacodynamics (PD), which accounts for the effects of the drug on the cells in the bone marrow, which is the location of the tumor generation.